A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

• ClinicalTrials.gov Identifier: NCT05095246
• Recruitment Status: Withdrawn
• First Posted: October 27, 2021
• Last Update Posted: August 14, 2023
• Sponsor: Krystal Biotech, Inc.
• Collaborator: Novotech (Australia) Pty Limited
• Information provided by (Responsible Party): Krystal Biotech, Inc.

Study Description

Brief Summary:

The Sponsor is developing KB407, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to the airways of people with cystic fibrosis via nebulization. This study is designed to evaluate safety and tolerability of KB407 in people with cystic fibrosis. This study will enroll 4 participants into each of the first two cohorts and will enroll five subjects into the last cohort. Cohort 1 will receive a single dose of KB407 and be followed for 60 days. Subjects in Cohort 1 may rollover into Cohort 2 at the Day 28 Visit. A Data Safety Monitoring Board (DSMB) will meet to determine study progress from Cohort 2 into Cohort 3. In Cohort 2, subjects will be dosed bi-weekly at Day 0 and Day 14. In Cohort 3 subjects will be dosed weekly at Day 0, Day 7, Day 14 and Day 21. All subjects will be followed for a year after the last dose of KB407.

Condition or disease	Intervention/treatment	Phase
Cystic Fibrosis	Biological: KB407 (Nebulization)	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I Study of Inhaled KB407, a Replication-Incompetent, Non-Integrating Vector Expressing Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), for the Treatment of Cystic Fibrosis
• Actual Study Start Date: March 8, 2022
• Estimated Primary Completion Date: July 1, 2024
• Estimated Study Completion Date: October 30, 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort 1 (KB407); A single dose of KB407 administered on Day 0	Biological: KB407 (Nebulization); Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
Experimental: Cohort 2 (KB407); Two (2) doses of KB407 administered at Day 0 and Day 14	Biological: KB407 (Nebulization); Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR
Experimental: Cohort 3 (KB407); Four (4) doses of KB407 administered at Day 0, Day 7, Day 14, and Day 21	Biological: KB407 (Nebulization); Nebulized solution of KB407, a replication-incompetent HSV-1 expressing full length human CFTR

Outcome Measures

Primary Outcome Measures :

1. To evaluate the safety and tolerability of KB407 in subjects with Cystic Fibrosis through adverse events as assessed by NCI-CTCAE v5.0 [ Time Frame: Baseline to End of the treatment assessed up to an average of 60 days ]
   Number of participants with treatment related adverse events as assessed by NCI-CTCAE v5.0

Secondary Outcome Measures :

1. To measure the difference in lung function over the course of the study, by change from baseline in forced expiratory volume (FEV1). [ Time Frame: Baseline to End of the treatment up to an average of 60 days ]
   Assessment of forced expiratory volume, in one second (FEV1,) will be assessed by pulmonary function test (PFT) as compared to baseline.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. The subject or legally appointed and authorized representative must have read, understood and signed an Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent Form and must be able to and willing to follow study procedures and instructions.
2. Male or female subject aged 18 years old or older at the time of Informed Consent.
3. A confirmed diagnosis of cystic fibrosis (CF) that is clinically stable, in the opinion of the Investigator.
4. FEV1 ≥50% and ≤100% of the predicted normal for age, gender, and height at Visit 1 (Screening).

Exclusion Criteria:

1. Initiation of any new chronic therapy (e.g., ibuprofen, hypertonic saline, azithromycin, Pulmozyme®, Cayston®, TOBI®) or any change in chronic therapy (excluding pancreatic enzyme replacement therapy) within 28 days of Visit 2 (Day 0).
2. Hospitalization, sinopulmonary infection, CF exacerbation, or other clinically significant infection or illness within 14 days of Visit 2 (Day 0) that, in the opinion of the Investigator, may confound study results.
3. A positive culture (saliva or sputum) indicating infection with highly virulent bacteria associated with accelerated decline in pulmonary function and/or decreased survival (e.g., Burkholderia cenocepacia, Burkholderia dolosa, Mycobacterium abscessus) within 6-months of Visit 2 (Day 0).
4. Participation in another clinical study or treatment with an investigational agent within 30 days or 5 half-lives, whichever is longer, of Visit 2 (Day 0).
5. History of lung transplantation.
6. Any condition (including a history or current evidence of substance abuse or dependence) that, in the opinion of the Investigator, would impact a subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of the Investigational Product (IP).
7. An active oral herpes infection within 30 Days of Visit 2 (Day 0).
8. Women who are pregnant or nursing.
9. Subject who is unwilling to comply with contraception requirements per-protocol.
10. Clinically significant abnormalities of hematology or chemistry testing at Visit 1 (Screening) that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment.
11. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol, in the opinion of the Investigator.

Contacts and Locations

Locations

Australia, New South Wales

Hunter Medical Research Institute

Newcastle, New South Wales, Australia, 2305

Sponsors and Collaborators

Krystal Biotech, Inc.

Novotech (Australia) Pty Limited

More Information

• Responsible Party: Krystal Biotech, Inc.
• ClinicalTrials.gov Identifier: NCT05095246
• Other Study ID Numbers: KB407-01
• First Posted: October 27, 2021
• Last Update Posted: August 14, 2023
• Last Verified: August 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Cystic Fibrosis; Fibrosis; Pathologic Processes; Pancreatic Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases; Genetic Diseases, Inborn; Infant, Newborn, Diseases